Lytix Biopharma presenting at major investor conferences in London and Stockholm in November
Oslo, 8 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Øystein Rekdal, CEO, will deliver oral presentations to institutional investors in London at the LSX Inv€$tival Showcase on the 13th of November, and attend the Jefferies Healthcare Conference on the 14th -16th November.
Investors interested in meeting should get in contact through the event partnering system or through the IR team.
Later in the month, on the 23rd of November, Dr Rekdal will give a presentation at the Redeye Life Science Day 2023 in Stockholm. There he will answer questions about the Company's latest positive developments, in particular, the preliminary Phase II data recently presented at ESMO - into the use of LTX-315 for the treatment of advanced melanoma.
The Redeye event can be watched live via the website https://www.redeye.se/events/915984/redeye-life-science-day-2023 and via a recording which will be made available afterwards.
Dr. Rekdal said: “We are looking forward to meeting with international investors at these conferences, to further raise awareness of the progress we have made with our unique approach to overcoming tumor heterogeneity by boosting a broad T-cell response. In particular, I am looking forward to presenting the encouraging preliminary clinical data that we announced at ESMO.”
For more information, please contact:
Gjest Breistein, CFO
E-Mail: [email protected]
Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: [email protected]
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.